USA flag logo/image

An Official Website of the United States Government

A new Instrument to Quantify Dyskinesia In Patients with Parkinson's Disease

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
79816
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
NS054344
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Koronis Biomedical Technologies Corp.
6901 East Fish Lake Road Suite #188 Maple Grove, MN 55369-5457
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: A new Instrument to Quantify Dyskinesia In Patients with Parkinson's Disease
Agency: HHS
Contract: 1R43NS054344-01
Award Amount: $98,124.00
 

Abstract:

DESCRIPTION (provided by applicant): Koronis Biomedical Technologies Corp. (KBT) proposes to create a new instrument to quantify dyskinesia in patients with Parkinson's disease, which currently affects 1.5 million Americans and is growing by an estimated 60,000 new cases each year. Recently there has been interest in quantifying dyskinesia, a side effect of the levodopa that is used to reduce Parkinsonian symptoms, for the evaluation of pharmacological and surgical interventions and as input to the levodopa dosing schedule. To date there has been a number of promising studies that have shown by making acceleration or gyroscopic measurement on various body segments that is it possible to develop algorithms that show good correlation to dyskinesias graded with either a modified abnormal involuntary movement (AIM) or the Goetz scale. The proposed instrumentation will eliminate the need to tether patients with wires, a shortcoming of current instruments, by using a low power, expandable, wireless network. The instrumentation will consist of two types of devices. The first device is a battery-powered, wireless, three axis gyroscope and accelerometer module whose volume is less than one cubic inch. The second device is a wearable wireless data recorder (shirt pocket size) that will collect the data from the modules. This will allow an ease of use not found in any other ambulatory system for motion capture. The expandable wireless network will enable simultaneous operation of several modules on different body segments. In Phase I, KBT will build a prototype, whose volume is not greater than one cubic inch, which will demonstrate the feasibility of developing modules that can synchronously measure and transmit their data. KBT will prove feasibility demonstrating the proposed system's performance is equal to or better than past research, which uses discrete wired sensors. In Phase II, KBT will complete the instrumentation development, experiment with detection algorithms, and validate the instrument and algorithms in clinical tests.

Principal Investigator:

Patrick A. Lichter
6127301091
PLICHTER@koronisbiotech.com

Business Contact:

Patrick Lichter
6127301091
PLICHTER@COMCAST.NET
Small Business Information at Submission:

KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT
KORONIS BIOMEDICAL TECHNOLOGIES CORPORATION 6901 E. Fish Lake Road Maple Grove, MN 55369

EIN/Tax ID: 411943230
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No